
Sirtex Medical Limited, the company behind the SRPT stock, is a global leader in cancer treatment.
The company's stock has shown significant growth over the years, with a strong track record of delivering returns to investors.
SRPT stock price has fluctuated, but it has consistently traded above its initial public offering (IPO) price of $6.50 per share.
Investors have been drawn to the company's innovative technology and its potential to revolutionize cancer treatment.
A unique perspective: Stock Quote Mvis
Financial Information
Sarepta Therapeutics's revenue in 2023 was $1.24 billion, a 33.26% increase from the previous year.
Their financial performance has been on the rise, with a notable decrease in losses from -$535.98 million in 2022 to -$535.98 million in 2023.
According to estimates, Sarepta Therapeutics's revenue is expected to reach $3,914 million by 2026, with a projected growth rate of 25.6% from 2025.
Here are some key financial metrics for Sarepta Therapeutics:
- Revenue (2023): $1.24 billion
- Revenue (2026 estimate): $3,914 million
- Net Loss (2023): -$535.98 million
- Net Profit (2026 estimate): $1,572 million
- EPS (2026 estimate): $15.64
These estimates suggest a strong growth trajectory for the company, with revenue expected to more than triple by 2026.
Estimates in USD
Sarepta Therapeutics' financial estimates for the next few years are looking promising. Revenue is expected to increase from $3,113 USD in 2025 to $4,438 USD in 2028.
The company's dividend yield is currently at 0.00%, indicating that they are not paying out any dividends. This could be a sign that they are reinvesting their profits back into the business to drive growth.
Earnings per share (EPS) are expected to rise from $11.74 in 2025 to $15.97 in 2028. This suggests that the company is generating more profits per share, which could lead to increased shareholder value.
The price-to-earnings (P/E) ratio is expected to range from 7.32 to 9.96, indicating that the stock may be undervalued compared to its earnings.
Here's a breakdown of Sarepta Therapeutics' revenue estimates for the next few years:
The number of analysts estimating revenue has ranged from 11 to 19, with an average estimate of $3,914 USD for 2026.
Income Statements (USD)
Sarepta Therapeutics's revenue in 2023 was $1.24 billion, a 33.26% increase from the previous year.
The company's revenue is projected to continue growing, with estimates suggesting it will reach $3.114 billion in 2025, $3.914 billion in 2026, $4.198 billion in 2027, and $4.438 billion in 2028.
Sarepta Therapeutics reported a net loss of -$535.98 million in 2023, a decrease of 23.81% compared to the previous year.
Net income is projected to turn positive in the future, with estimates suggesting it will be $1.134 billion in 2025, $1.572 billion in 2026, $1.577 billion in 2027, and $1.698 billion in 2028.
Here's a breakdown of the company's estimated income statements for 2025 and 2026:
Sarepta Therapeutics's estimated earnings per share (EPS) for 2025 and 2026 are $11.74 and $15.64, respectively.
Company News and Events
Sarepta Therapeutics has a history of releasing quarterly earnings reports, with the most recent one being Q3 2024 Earnings Release on November 6, 2024, reporting an actual EPS of 0.340 USD.
The company also hosts annual general meetings, with the most recent one being on June 6, 2024, where an actual EPS of -5.800 USD was reported.
Here's a list of notable events in the past few years:
- Q4 2023 Earnings Release: Actual EPS of 0.470 USD on February 28, 2024
- Annual General Meeting: Actual EPS of -8.030 USD on June 8, 2023
- Q2 2023 Earnings Release: Actual EPS of -0.270 USD on August 2, 2023
News
Sarepta Therapeutics has announced positive topline results from Part 2 of EMBARK, a study on their precision genetic medicine for rare diseases.
The company will present at the 43rd Annual J.P. Morgan Healthcare Conference, where senior management will share their insights.
Sarepta Therapeutics is the leader in precision genetic medicine for rare diseases, according to their announcement.
Their ELEVIDYS treatment has shown promising results, with increases on the North Star Ambulatory Assessment (NSAA) at one year in crossover patients.
MRI results at two years will provide further insight into the effectiveness of their treatment.
Past Events
Sarepta Therapeutics has had its fair share of earnings reports over the years. In Q3 2024, their earnings per share (EPS) was $0.340 USD.
The company's quarterly earnings reports have shown some fluctuations. For example, in Q2 2024, their EPS was $0.070 USD, which is a significant decrease from the previous quarter.
Sarepta Therapeutics also hosts annual general meetings, where shareholders gather to discuss company business. The most recent one was on June 6, 2024, and it resulted in a loss of $5.800 USD.
Here's a breakdown of their quarterly earnings reports:
Analyst Insights
According to 21 analysts, the average rating for SRPT stock is "Buy".
The 12-month stock price forecast is a significant increase of 52.65% from the latest price, which is a promising sign for investors.
The forecasted stock price is $179.38, a substantial jump that could be a major opportunity for those looking to invest in SRPT stock.
Frequently Asked Questions
What is the outlook for Sarepta Therapeutics?
According to analyst forecasts, Sarepta Therapeutics is expected to see a significant increase in stock value, with an average predicted rise of 47.15% from its current price. Analysts' 12-month price forecasts range from 75 to 230, with an average target of 179.38.
What is the target price for SRPT?
The target price for Sarepta Therapeutics (SRPT) is $183.79, according to the latest estimates. This suggests a potential investment opportunity for those interested in the company's future performance.
Is Sarepta a good buy?
Sarepta (SRPT) is considered a strong buy by street analysts, ranking 10th in our list of top-performing biotech stocks in 2024
Featured Images: pexels.com


